N-methylnitrilotriacetamide | 146377-45-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-methylnitrilotriacetamide
• 英文别名: 2-[(2-amino-2-oxoethyl)-[2-(methylamino)-2-oxoethyl]amino]acetamide
• CAS: 146377-45-9
• 化学式: C₇H₁₄N₄O₃
• mdl: MFCD24390682
• 分子量: 202.213
• InChiKey: RDAVMXCBNGZRSP-UHFFFAOYSA-N

物化性质

• 沸点：
  575.7±45.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,2,2-氮川三乙腈 在 硫酸 、 水 作用下， 以 水 为溶剂， 生成 N-methylnitrilotriacetamide
  参考文献：
  名称：

  Facile synthesis of substituted nitrilotriacetamides

  摘要：

  Ligands which contain multiple amide groups represent interesting possibilities as chelating agents. We report here a facile synthesis and crystal structure of nitrilotriacetamide, 2, a neutral tetradentate ligand which we have been studying for metal complexation. Also described herein is a divergent synthesis of the mono, di- and trimethylated and dimethyl-monoalkyl derivatives of 2.

  DOI：

  10.1016/0040-4039(93)88040-p

文献信息

• Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11041009B2

  公开（公告）日：2021-06-22

  An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

  本文描述了一种包含或由三价糖簇组成的胰岛素共轭物。在特定方面，该胰岛素共轭物显示出一种药代动力学（PK）和/或药效学（PD）特征，即使在没有外源多价糖结合分子（如 Con A）的情况下给需要它的受试者用药时，也能对葡萄糖或α-甲基甘露糖等糖类的全身浓度做出反应。
• GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20200087375A1

  公开（公告）日：2020-03-19

  An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
• CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20210177981A1

  公开（公告）日：2021-06-17

  The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain). In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
• US9884125B2
  申请人：——

  公开号：US9884125B2

  公开（公告）日：2018-02-06